Skip to main content

Published locations for Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval

User login

  • Reset your password
  • /content/pembrolizumab-dmmr/msi-h-tumors-marks-first-tumor-agnostic-fda-approval
  • /jcso/article/154582/gastroenterology/pembrolizumab-dmmr/msi-h-tumors-marks-first-tumor-agnostic-fda
  • /hematology-oncology/article/154582/gastroenterology/pembrolizumab-dmmr/msi-h-tumors-marks-first